US LNG exports surge but will buyers in China turn up?
NEW YORK - J.P. Morgan SE, acting as the Stabilisation Coordinator, has announced the possibility of market stabilization activities related to Teva Pharmaceutical (NYSE:TEVA) Finance Netherlands II BV and Teva Pharmaceutical Finance Netherlands III BV’s new securities offering. The securities in question are USD-denominated senior unsecured notes with 5.5 and 7.5-year maturities, set to be listed on the New York Stock Exchange.
The stabilization period, which is expected to commence today, is part of a strategy to support the market price of the securities post-issuance. This period is anticipated to last no longer than June 20, 2025. During this time, the Stabilising Manager(s) may over-allot securities up to 5% beyond the aggregate nominal amount offered.
The stabilization actions, which may include over-allotment or transactions to maintain market prices, are not guaranteed to take place and can be halted at any time. They are subject to regulatory limits ensuring that any over-allotment does not exceed 105% of the aggregate principal amount of the securities.
J.P. Morgan SE is coordinating the stabilization, with BNP Paribas (OTC:BNPQY), BofA Securities, HSBC, and IMI-Intesa Sanpaolo participating as Stabilisation Managers. The stabilization trading activities, if initiated, will occur over the counter.
The announcement clarifies that the securities are not being offered or sold within the United States, as they have not been registered under the United States Securities Act of 1933. Consequently, the securities cannot be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements.
This information is based on a press release statement and is intended for professional investors and high net worth individuals in the United Kingdom (TADAWUL:4280), as well as qualified investors in the European Economic Area, in compliance with respective regulations. The details provided are for informational purposes only and do not constitute an offer to underwrite, subscribe for, or acquire any securities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.